Allergies News and Research

Latest Allergies News and Research

Warming climate may increase risk from Chagas disease

In the spring of 1835, Charles Darwin was bitten in Argentina by a "great wingless black bug," he wrote in his diary. "It is most disgusting to feel soft wingless insects, about an inch long, crawling over one's body," Darwin wrote, "before sucking they are quite thin, but afterwards round & bloated with blood."

16 Mar 2012

Serious climate change-related health problems will affect the world's population

Worldwide increases in the incidences of asthma, allergies, infectious and cardiovascular diseases will result from a variety of impacts of global climate change, including rising temperatures, worsening ozone levels in urban areas, the spread of desertification, and expansions of the ranges of communicable diseases as the planet heats up, the professional organization representing respiratory and airway physicians stated in a new position paper released today.

16 Mar 2012

Allergy-free egg in the making

Researchers at CSIRO and experts at Geelong's Deakin University have found a way to “switch off” four egg allergens. These modified eggs could produce chickens that lay hypoallergenic eggs but the genes and DNA of the chicken would remain unaltered.

15 Mar 2012

Wireless asthma inhaler training device could help save thousands of A&E visits and lives

Many asthma patients are not trained adequately to inhale from asthma inhaler devices. This is a problem that can be both serious and expensive considering some 5,000 people visit the emergency room due to and 11 people die from asthma every day, according to the Asthma and Allergy Foundation of America.

13 Mar 2012

Researchers identify genetic signature for eosinophilic esophagitis

Researchers have identified a genetic signature for a severe, often painful food allergy – eosinophilic esophagitis – that could lead to improved diagnosis and treatment for children unable to eat a wide variety of foods.

12 Mar 2012

Positive phase II trial results from Circassia's ragweed allergy therapy

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ragweed allergy therapy has achieved positive results in a key phase II clinical trial.

8 Mar 2012

Majority of Missourians continue to favor nonprescription access to PSE-containing medicines

The Consumer Healthcare Products Association (CHPA) released today a recent poll that found a majority of Missourians -- by a margin of 16 percent -- continue to favor nonprescription access to safe and effective medicines containing pseudoephedrine (PSE), such as Advil Cold & Sinus, Allegra-D, Claritin-D, Mucinex-D, and Sudafed over a prescription mandate.

7 Mar 2012

Timely treatment with Berinert provides faster symptom relief for HAE patients

CSL Behring announced today that treatment with Berinert, C1 Esterase Inhibitor (Human) within six hours of the onset of an acute hereditary angioedema (HAE) attack provides faster symptom relief than later treatment, according to data presented at the 2012 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

7 Mar 2012

Rep. Sensenbrenner sends 'fact-finding letter' to White House science adviser about bird flu studies

"Representative Jim Sensenbrenner (R-Wis.), a former head of the House committees on science and the judiciary, and currently vice chair of the House Committee on Science, Space, and Technology, last week sent a 'fact-finding letter' to White House science adviser John Holdren, asking pointed questions about how the U.S. government has handled the controversy" surrounding two studies that showed how H5N1 bird flu virus could be manipulated to become transmissible among ferrets, a model for humans, "and questioning whether it should have funded the two flu studies," ScienceInsider reports.

6 Mar 2012

Merck announces results from AIT Phase III clinical study for ragweed allergy

Merck, known as MSD outside the United States and Canada, today announced the results from a Phase III clinical study of its investigational allergy immunotherapy tablet (AIT) for ragweed pollen.

6 Mar 2012

Santarus fourth quarter total revenues increase 65% to $42.6M

Santarus, Inc. (NASDAQ: SNTS) today reported financial and operating results for the three and 12 month periods ended December 31, 2011.

5 Mar 2012

Snoring toddlers may develop behavioural problems later: Study

A new study shows that babies and toddlers who snore, gasp for breath, or breathe with their mouth open while sleeping may be at a greater risk of behavioural problems all the way through second grade.

5 Mar 2012

Merck announces success of pill against ragweed allergy

Merck & Co. announced Monday that their experimental allergy tablet reduced allergic reactions to ragweed and helped patients use less medication to treat their symptoms.

5 Mar 2012

Meda announces positive results from three MP29-02 studies on allergic rhinitis

Meda announced today positive results of three studies of MP29-02 (tentatively called Dymista), a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate.

5 Mar 2012

Study: Bioavailability similar among four subcutaneous IgG preparations

Data presented by CSL Behring today suggest that the bioavailability of immunoglobulin G (IgG) therapies is consistent when patients with primary immunodeficiencies switch from one IgG product to another by the subcutaneous route.

5 Mar 2012

Consensus across studies promises to enhance NIH-supported asthma clinical research

A consortium of federal agencies and nongovernmental organizations has published a report proposing a set of common measures and data-collection methods for use in asthma clinical research.

3 Mar 2012

New outcome measures may reduce disparities in children with asthma

Newly proposed asthma outcome measures will help standardize and improve results from the hundreds of millions of dollars the National Institutes of Health (NIH) spends annually to study asthma, according to the Merck Childhood Asthma Network, Inc. (MCAN), the nation's only organization focused solely on childhood asthma.

3 Mar 2012

Long-term data from Baxter's HyQ clinical study on PI

Baxter International Inc. today announced the presentation of additional long-term data supporting the clinical profile of HyQ, its investigational combination product for use in patients with primary immunodeficiencies.

From Baxter International Inc. 3 Mar 2012

A longer spring allergy season due to winter's warmer-than-average temperatures

While this winter's warmer-than-average temperatures were a nice contrast for people who suffered through to last year's many winter storms, many may now pay for the balmy temperatures with an earlier and longer spring allergy season. For some, symptoms such as runny nose, nasal congestion, sneezing, itchy eyes, ears and throat, wheezing and shortness of breath have already begun and may last into early summer.

2 Mar 2012

New HS44 molecule inhibits lung metastasis

One type of white blood cell, the Natural Killer T Cells, fights against infections and tumours by freeing cytokine proteins which activate the body's immune response and destroy infected or malignant cells. To do so they must receive an activation signal. Specific receptors located on their surface act as switches: they activate the lymphocyte in presence of an antigen, a molecule which triggers alarm signals.

2 Mar 2012